Paweł Steckiewicz

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

Elżbieta Iskierka‐Jazdzewska, Marek Hus, Krzysztof Giannopoulos et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 39 citations

Medicine, Oncology, Pharmacology +14

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study

Elżbieta Iskierka‐Jazdzewska, Monika Długosz‐Danecka, Agnieszka Szymczyk et al. · Anticancer Research · 2020 · 17 citations · Full text

Medicine, Oncology, Pharmacology +13

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

Bartosz Puła, Katarzyna Pruszczyk, Ewa Pietrusza et al. · Cancers · 2022 · 15 citations · Full text

Veterinary Medicine, Hematology, Infectious Diseases +14

Ibrutinib discontinuation in patients with relapsed or refractorychronic lymphocytic leukemia treated in acompassionate use program:A report from the Polish Adult Leukemia Study Group (PALG)

Elżbieta Iskierka‐Jazdzewska, Bartosz Puła, Agnieszka Szeremet et al. · Advances in Clinical and Experimental Medicine · 2019 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group

Anita Soboń, Joanna Drozd‐Sokołowska, Ewa Paszkiewicz‐Kozik et al. · Annals of Hematology · 2023 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +15